DSIP 5 mg

How it works

DSIP, or delta sleep-inducing peptide, is a nine-amino-acid peptide first reported in 1977 after experiments involving rabbit cerebral venous blood and delta-wave EEG activity.^[2] FDA uses the name emideltide for the same reported sequence and distinguishes its free-base and acetate forms as separate bulk substances.^[19] Older reviewers also cautioned that some "DSIP-like immunoreactivity" may reflect related fragments rather than intact peptide.^[3]

Despite its name, DSIP is not an established sleep medication. Its clinical literature is small, old, formulation-ambiguous, and methodologically limited.

Benefits & side effects

The original evidence comes from rabbit and rat experiments examining EEG and sleep-stage changes.^[2] Small human studies followed, but FDA's 2026 review found the insomnia results inconclusive and preliminary: some tiny intravenous studies reported sleep changes, while other double-blind placebo-controlled studies found no significant objective or subjective benefit.^[19]

FDA found no data supporting the nominated subcutaneous route for chronic insomnia, narcolepsy, or opioid withdrawal, and current clinical guidelines do not discuss emideltide for those conditions.^[19] Claims about lucid dreaming or a standard sleep-enhancement regimen are unsupported.